Featured Stock


Astria Therapeutics is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...


Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...


Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein...

March 27
Last Trade: 10.65 0.14 1.33

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)...Read more

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

March 27
Last Trade: 0.52 0.08 19.13

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation...Read more

Delcath Systems Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14, 2023

March 27
Last Trade: 5.70 0.86 17.77

NEW YORK, March 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the US Food and Drug Administration (FDA) has accepted Delcath Systems, Inc.'s (Delcath) new...Read more

FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer

March 27
Last Trade: 1.58 0.09 5.70

Data presented at plenary session of Society of Gynecologic Oncology Meeting  Patients treated suffered from platinum resistant/refractory ovarian cancer Previous PD-(L)1/CTLA-4  combinations have reported only 3-10% responses in comparable patient populations1,2 Findings...Read more

AstraZeneca: Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy...

March 27
Last Trade: 69.12 1.21 1.78

WILMINGTON, Del. / Mar 27, 2023 / Business Wire / Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were...Read more

Ionis Pharmaceuticals reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN

March 27
Last Trade: 34.12 0.17 0.50

Eplontersen met co-primary endpoints demonstrating sustained reduction in TTR and benefits in neuropathy and quality of life through 66 weeks 35 and 66-week data to be presented at the American Academy of Neurology (AAN) Annual Meeting in April CARLSBAD, Calif., March 27, 2023...Read more

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...


Biggest Gainers

CompanyChangeLast Trade
Mettler-Toledo 9.36 0.64 $1,469.11
Elevance Health 7.06 1.55 $463.75
Repligen 6.72 4.19 $166.98
Novartis 6.12 7.32 $89.71
Reata Pharmaceuticals 5.31 6.20 $91.01
Bio-Rad Laboratories 5.20 1.13 $465.98
Humana 5.02 1.00 $507.45
Thermo Fisher Scientific 4.56 0.82 $562.82
CONMED 4.18 4.31 $101.18
Teleflex 4.00 1.61 $252.94
UnitedHealth 3.98 0.84 $479.97
ResMed 3.24 1.52 $215.83
Chemed 3.23 0.62 $526.00
Catalent 3.07 4.78 $67.34
BeiGene 2.66 1.21 $222.37
DexCom 2.65 2.32 $116.74
Madrigal Pharmaceuticals 2.51 1.07 $237.18

Highest Volume

CompanyVolumeLast Trade
Signify Health 28,326,293 $30.48
Pyxis Oncology 23,933,505 $2.79
Coeptis Therapeutics 9,312,236 $1.65
Gamida Cell 6,107,119 $0.96
Jounce Therapeutics 5,586,789 $1.85
Cyclerion Therapeutics 5,586,547 $0.52
Pfizer 5,529,726 $40.28
Codiak BioSciences 5,360,236 $0.23
Novo Integrated Sciences 5,034,479 $0.13
Ginkgo Bioworks 4,764,118 $1.24
Aptinyx 4,691,995 $0.14
Healthcare Triangle 4,621,896 $0.46
Iovance Biotherapeutics 4,391,700 $6.13
Clover Health 3,753,111 $0.83
Unity Biotechnology 3,690,580 $2.13
Ardelyx 3,645,369 $4.21
Cidara Therapeutics 3,431,903 $1.03
  • Upcoming FDA Catalysts

    • Entera Bio (NASDAQ: ENTX) FDA Meeting

      March 30, 2023
    • BioMarin Pharmaceutical (NASDAQ: BMRN) Data Presentation

      March 31, 2023
    • BioVie (NASDAQ: BIVI) Data Presentation

      April 1, 2023
    • Hillstream BioPharma (NASDAQ: HILS) Data Presentation

      April 17, 2023
    • Jazz Pharmaceuticals (NASDAQ: JAZZ) Data Presentation

      April 17, 2023
    • Ascendis Pharma (NASDAQ: ASND) PDUFA Date

      April 30, 2023

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...


Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is installed...


Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities: